CD19 and B-cell acute lymphoblastic leukemia: Targeting a single AML-associated antigen could lead to an antigen-negative relapse similar to the CD19-negative relapses (CD—cluster of differentiation) during B-cell acute lymphoblastic leukemia treatment with CD19 targeting [1].